Results 121 to 130 of about 18,455 (220)

Síntesis y radiomarcado de un conjugado heterobivalente de bombesina y ácido fólico para la evaluación de la actividad metabólica de células de cáncer de mama [PDF]

, 2017
Las moléculas heterobivalentes radiomarcadas han mostrado ser una estrategia adecuada para obtener imágenes del tumor de manera sensible, específica y no invasiva debido a que interactúan concomitantemente con diferentes blancos moleculares sobre la ...
ARANDA LARA, LILIANA, ARANDA LARA, LILIANA   +1 more
core  

Targeted delivery of anti-inflammatory therapy to rheumatoid tissue by fusion proteins containing an IL-4-linked synovial targeting peptide [PDF]

, 2011
We provide first-time evidence that the synovial endothelium-targeting peptide (SyETP) CKSTHDRLC successfully delivers conjugated IL-4 to human rheumatoid synovium transplanted into SCID mice. SyETP, previously isolated by in vivo phage display and shown
Ahuva Nissim, Ciara M. Finucane, Costantino Pitzalis, Danielle DiCara, Michele Bombardieri, Rita Jones, Sarah E. Wythe, Stephen J. Mather, Taher E. I. Taher, Y. K. Stella Man, Yuti Chernajovsky   +10 more
core   +1 more source

Management of Peptide Receptor Radionuclide Therapy Toxicities in Neuroendocrine Neoplasm Patients. [PDF]

Curr Treat Options Oncol
Mohindroo C, Ramirez RA.
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy-Induced Hypercortisolemic Crisis in Ectopic Cushing Syndrome. [PDF]

JCEM Case Rep
Pandit R, Yamichannaiah C, Lila AR, Karlekar M, Memon SS, Bandgar T.   +5 more
europepmc   +1 more source

Safety and efficacy of peptide receptor radionuclide therapy for advanced medullary thyroid cancer: a systematic review and meta-analysis. [PDF]

Thyroid Res
Abdlkadir AS, Al-Adhami D, Shi H, Sathekge MM, Sheikha AA, Mohamad I, Kreissl M, Al-Ibraheem A.   +7 more
europepmc   +1 more source

¹⁷⁷Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumors: a systematic review and meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Wang J, Pang X, Lian J, Lu H.
europepmc   +1 more source

Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [¹⁷⁷Lu]Lu-DOTA-MGS5 in Patients with Small Cell Lung Cancer. [PDF]

Pharmaceutics
Zavvar TS, Santo G, Gruber L, Kronthaler A, Hagenbuchner J, Skvortsova I, Piro I, Steiger K, Martinovic V, Minasch D, Löffler-Ragg J, di Santo G, Virgolini IJ, von Guggenberg E.   +13 more
europepmc   +1 more source

Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial. [PDF]

Front Endocrinol (Lausanne)
Kolodziej M, Opalinska M, Mikolajczak R, Hubalewska-Dydejczyk A, Dedecjus M, Kowalska A, Saracyn M, Garnuszek P, Cieszykowska I, Januszkiewicz-Caulier J, Dlugosinska J, Durma AD, Jozwik-Plebanek K, Mroz A, Janiak K, Gasior-Perczak D, Trofimiuk-Muldner M, Sowa-Staszczak A, Braziewicz J, Lenda-Tracz W, Kacperski K, Budzynska A, Kubik A, Pastusiak P, Chalewska W, Borkowska A, Cegla P, Walecka-Mazur A, Szczodry A, Kaminski G.   +29 more
europepmc   +1 more source

Peptide receptor radionuclide therapy in G3 gastroenteropancreatic neuroendocrine tumors: a missed opportunity for European patients? [PDF]

Lancet Reg Health Eur
Panzuto F, Cives M, Strosberg J.
europepmc   +1 more source

Machine Learning Uncovers Novel Predictors of Peptide Receptor Radionuclide Therapy Eligibility in Neuroendocrine Neoplasms. [PDF]

Cancers (Basel)
Sipka G, Farkas I, Bakos A, Maráz A, Mikó ZS, Czékus T, Bukva M, Urbán S, Pávics L, Besenyi Z.   +9 more
europepmc   +1 more source